Genelabs Technologies News
Most Popular Genelabs Technologies Story
GSK buys Genelabs for $57M
In a move designed to bolster it's hepatitis C offerings, GlaxoSmithKline is buying Redwood City, CA-based Genelabs Technologies for $57 million. GSK will pay $1.30 per share for outstanding Genelabs Read more...
Latest Headlines
- October 30, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
